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Aim: To systematically update evidence on the efﬁcacy of using probiotics for the pre-
vention of healthcare-associated diarrhea in children. Methods: MEDLINE, EMBASE, The
Cochrane Library, Health Source: Nursing/Academic Edition, two clinical trials and refe-
rence lists were searched in June 2013, for randomized controlled trials (RCTs) performed
in children aged 1 month to 18 years that compared the effects of the administration of
probiotics with placebo or no intervention. The primary outcome measure was the inci-
dence of healthcare-associated diarrhea. Results: Six RCTs involving 1343 children met
the inclusion criteria. Administration of Lactobacillus rhamnosus GG (LGG) compared with
placebo reduced the risk of healthcare-associated diarrhea (2 RCTs, n = 823, RR 0.37; 95%
CI 0.23–0.59), reduced the risk of rotavirus gastroenteritis (3 RCTs, n = 1043, RR 0.49, 95%
CI 0.28–0.86), but did not reduce the risk of asymptomatic rotavirus infection (2 RCTs,
n = 301, RR 1.39, 95% CI 0.74–2.62). Administration of Biﬁdobacterium biﬁdum & Streptococcus
thermophilus compared with placebo reduced the risk of healthcare-associated diarrhea (1
RCT, n = 55, RR 0.22, 95% CI 0.05–0.96), rotavirus gastroenteritis (1 RCT, n = 55, RR 0.27,
95% CI 0.08–0.87), and rotavirus asymptomatic infection (1 RCT, n = 55, RR 0.27, 95% CI
0.08–0.87). Administration of two other probiotics (i.e., Lactobacillus reuteri DSM 17938 and
Lactobacillus delbrueckii H2B20) was ineffective. Conclusion: In hospitalized children, the
administration of LGG, compared with placebo, reduced the incidence of healthcare-asso-
ciated diarrhea, including rotavirus diarrhea. Evidence on the effects of other probiotics,
whether positive or negative, is limited.
© 2013 Polish Pediatric Society. Published by Elsevier Urban & Partner Sp. z o.o. 
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Healthcare-associated infections (HCAI) are deﬁned as those
occurring 48 h or more after admission to a hospital. They
are a major problem for a patient's safety and are linked to
a prolonged hospital stay, long-term disability, increased
resistance of microorganisms to antimicrobials, massive
additional ﬁnancial burden, and excess deaths [1]. The risk
of acquiring HCAI is international and varies between 5%
and 15% [1]. In children, gastrointestinal infections, particu-
larly of rotavirus origin, remain a leading cause of HCAI [1].
A recent meta-analysis showed that the risk of developing
rotavirus healthcare-associated diarrhea was 2.9 per 100
hospitalizations, and the risk was higher during epidemic
months (8.1:100 hospitalizations) [1].
Prevention of HCAI is a priority for settings and institu-
tions committed to making healthcare safer. However, it is
a challenge. Next to the isolation of sick patients, one of the
cheapest interventions, although not fully satisfying, is
improved hand hygiene according to the World Health
Organizations' guidelines [2]. There are data suggesting
a positive impact of mass vaccination against rotavirus on
a reduction in nosocomial rotavirus gastroenteritis among
pediatric patients [3]. Unfortunately, the high cost of these
vaccines is an obstacle to their widespread use in many
countries, thus maintaining interest in simple, effective,
low-cost strategies for preventing HCAI.
Probiotics are live microorganisms thought to improve the
microbial balance of the host, counteract disturbances in
intestinal ﬂora, and reduce the risk of colonization by
pathogenic bacteria [4]. In children, there are convincing data
to support the use of probiotics with documented efﬁcacy for
the treatment of acute gastroenteritis and the prevention of
antibiotic-associated diarrhea [5, 6]. Previously, we documen-
ted that in hospitalized children, the administration of
Lactobacillus rhamnosus GG (LGG), compared with placebo,
reduced the overall incidence of healthcare-associated diarr-
hea, including rotavirus gastroenteritis [7].
The objective of this systematic review and meta-analy-
sis, which adds to our previous report [8], was to systemati-
cally review data on the efﬁcacy of use of various probiotics,
alone or in combination, for the prevention of healthcare-
associated diarrhea in children. Only data related to
a speciﬁc probiotic strain or their combinations are reported.
This is because it is known that not all probiotics are equal,
and pooling data on different probiotics have been repea-
tedly questioned [8, 9].
Methods
The methods for this systematic review and meta-analysis
were described in detail in our earlier review [8]. In brief, the
guidelines from the Cochrane Collaboration for undertaking
and reporting the results of a systematic review and meta-
analysis and the PRISMA statement [10] were followed.
Randomized controlled trials (RCTs) reporting incidence
outcomes for healthcare-associated diarrhea were conside-
red for inclusion. Participants had to be children aged1 month to 18 years who were admitted to the hospital for
any reason other than gastrointestinal infections. The
interventions of interest compared use of probiotics (any
strain or dose) versus placebo or no treatment for the
prevention of healthcare-associated diarrhea. The primary
outcome measure was the incidence of healthcare-associa-
ted diarrhea as deﬁned by the investigators. The secondary
outcome measures were the incidence of rotavirus gas-
troenteritis, the incidence of asymptomatic rotavirus infec-
tion, the duration of diarrhea, and the duration of hospita-
lization.
We searched MEDLINE, EMBASE, The Cochrane Library,
including the Cochrane Central Register of Controlled Trials,
Health Source: Nursing/Academic edition, and reference
lists, with no language restrictions, through June 2013. The
search strategy included the use of a validated ﬁlter for
identifying RCTs, which was combined with a topic-speciﬁc
strategy using the following PubMed MeSH terms: 1. (pre-
vention OR prevent OR prevent* OR preventive therapy OR
prophylaxis); 2. (diarrhea OR diarrhoe* OR diarhe* OR dysen-
ter* OR gastro enteritis OR diarrhea OR diarrh* OR gastritis
OR gastrit* OR gastroenteritis OR gastroenterocolitis OR
vomit* OR intestinal infection* OR gastrointestinal infection*
OR rotavirus); 3. (lactobacillus OR lactobacill* OR
l acidophilus OR l casei OR l delbrueckii OR l helveticus
OR l johnsonii OR l paracasei OR l plantarum OR l reuteri OR
l rhamnosus OR l salivarius); 4. (Sacharomyces OR saccharo-
myce* OR s bulardii OR streptococcus OR streptococc* AND
thermophilus OR enterococcus OR enterococc* AND fae-
cium); 5. (Biﬁdobacterium OR biﬁdobacter* OR b animalis OR
b biﬁdum OR b breve OR b infantis OR b lactis OR b longum);
6. 3 OR 4 OR 5; 7. 6 AND 1 AND 2. In addition, we searched
two trial registries (ClinicalTrials.gov, www.clinicaltrials.gov,
and EU Clinical Trials Register, www.clinicaltrialsregister.
eu).
Using a standardized data extraction form, one author
(MW) extracted the following data items: author, year of
publication, language, study setting, methodological design,
exclusion criteria for participants, patient characteristics (age,
diagnosis), number of patients allocated to each group, types
of interventions, and outcome measures. The data were
entered into a computer program. The Cochrane Review
Manager (RevMan) (version 5.2.6 Copenhagen: The Nordic
Cochrane Centre, The Cochrane Collaboration, 2013) was used
for statistical analysis and to perform a meta-analysis of the
RCTs.
The risk of bias was assessed as described in the
Cochrane Handbook for Systematic Reviews of Interven-
tions, and it included the assessment of the adequacy of
sequence generation, allocation concealment, blinding of
participants and personnel, blinding of outcome assessors,
and the extent of loss to follow-up (i.e., incomplete outcome
data). In all cases, an answer of 'yes' indicates a low risk of
bias, and an answer of 'no' indicates a high risk of bias [11].
Heterogeneity was quantiﬁed by x2 and I2. The quantity,
I2, describes the percentage of total variation across studies
that is due to heterogeneity rather than to chance. Negative
values of I2 are made equal to zero so that I2 lies between
0% and 100%. A value of 0% indicates no observed heteroge-
neity, and larger values show increasing heterogeneity. The
Records identifie d through data base
Medline n = 1 36
Embase n =433
Cochrane n = 70
Heal th Source: Nursi ng/Acade mic 
Edit ion  n = 75
Records scree ned
(n = 71 4)
Records after  duplicates  remov ed
(n = 71 4)
Addit ional reco rds id entified 
through other sources
(n = 0)
Studies included  in 
quantitat ive synthesis 
(meta -analysis) (n = 6)
Full -te xt a rticles 
assessed for eligibility
(n = 10 )
Full -te xt a rticles 
excluded,  reas ons:  not 
meeti ng inclusi on 
criteria (n = 4)
Reco rds  excluded
(n = 704 )
Fig. 1 – Identification process for eligible trials
Ryc. 1 – Proces identyfikacji badań
p e d i a t r i a p o l s k a 8 9 ( 2 0 1 4 ) 8 – 1 610results for individual studies and pooled statistics are
reported as the risk ratio (RR) between the experimental and
control groups with 95% conﬁdence intervals (95% CI). The
data were analyzed using RevMan.
Results
Description of studies
Fig. 1 shows the ﬂow of studies through the selection
process. A total of 714 records were identiﬁed from the
primary electronic databases. Ten potentially relevant stu-
dies were identiﬁed for full-text review. Six RCTs met the
inclusion criteria [12–17]. The characteristics of the included
trials are presented in Table I. Excluded studies are descri-
bed in Table II. The included RCTs randomized a total of
1343 patients (690 in the experimental group and 653 in the
control group). Five included studies were double blind,
placebo-controlled trials [13–16, 18]. All trials had somemethodological limitations such as unclear allocation con-
cealment [13–15, 17] and/or no intention-to-treat analysis
[14, 18].
Population
Patients were hospitalized in pediatric departments for
acute or chronic diseases. In the study by Saavedra et al.
[18], children were admitted to a chronic medical care
hospital. The most common reason for hospitalization
was upper respiratory tract infection. One exception was
the study by Hojsak et al. [13], in which children with
respiratory tract infections were excluded, as this was one
of the outcomes. Patients' ages ranged from 1 month to 18
years. Five RCTs [14–18] included only infants and young
children under the age of 48 months. In contrast, in the
study by Hojsak et al. [13], the mean age of the partici-
pants was 9.9 years, and children below the age of 12
months were excluded. Exclusion criteria for participants
were mostly similar and included breastfeeding [15, 16,
Table I – Methodological quality summary and characteristics of included studies
Tabela I – Wiarygodność metodologiczna i charakterystyka włączonych badań
Author (country) Methodological quality summarya Characteristics of included trials
Adequate sequence
generation
Allocation
concealment
Blinding Population Exp/Cont
(Follow-up)
Probiotic dose Control Duration of
intervention
(follow-up period)
Primary outcome
(deﬁnition)
Hojsak et al.
(Croatia) [13]
Yes (computer-
generated numbers)
Unclear Yes (DB) >12 mo with acute
and/or chronic
diseases (mean
age: 10  5 y)
376/366 (100%) LGG 109 CFU daily in
100 ml of fermented
milk product
Placebo (post-
pasteurized
fermented milk
product without
LGG)
During hospital
stay (7 days after
discharge)
Gastrointestinal tract
infections (diarrhea
with 3 loose or
watery stools within
24 h with or without
vomiting). AAD was
not considered.
Mastretta et al.
(Italy) [14]
No (odd and even
random
sampling numbers)
Unclear Yes (DB) 1–18 mo with acute
and/or chronic
diseases (mean
age: 10 mo)
134/135
(follow up
114/106, i.e., 82%)
LGG 2 capsules of
1010 CFU on
admission, and 1
capsule daily during
hospitalization
Placebo
(oligosaccharides)
During hospital
stay (3 days after
discharge)
Rotavirus infections
(diarrhea deﬁned as
3 loose stools at
least 24 h after
admission with
Rotavirus antigen
detected in stool
sample)
Szajewska et al.
(Poland) [15]
Unclear (as reported
in the paper);
computer –generated
numbers as
clariﬁed by the
authors
Unclear Yes (DB) 1–36 mo with acute
and/or chronic
diseases (mean
age: 11 mo)
45/36 (100%) LGG 6  109 CFU in 1
sachet twice daily
Placebo
(maltodextrin)
During hospital
stay (3 days after
discharge)
Diarrhea (3 loose or
watery stools in a 24-h
period). AAD was not
excluded
Wanke et al.
(Poland) [16]
Yes (computer-
generated numbers)
Yes (independent
person prepared
the randomization
schedule and
oversaw the
packaging and
labeling of the
study products)
Yes (DB) 1 to 48 mo with
acute and/or
chronic diseases
(mean age: 11.5
mo)
54/52 (100%) L. reuteri DSM 17938
108 CFU in 5 drops
daily
Placebo During hospital
stay (3 days after
discharge)
Diarrhea (3 loose or
watery stools in a 24-h
period). AAD was not
excluded
Penna et al.
(Spain) [17]
Yes (computer-
generated numbers)
Unclear Unclear 1–36 mo with acute
and/or chronic
diseases
72/67 (100%) L. delbruecki 2.6  108
in fermented milk
product
Placebo During hospital
stay
Diarrhea (3 loose or
watery stools in a 24-h
period)
Saavedra et al.
(North America) [18]
Yes (block
randomization)
Yes Yes (DB) 5–24 mo with
chronic diseases
(mean age 11 mo)
29/26 (100%) Milk formula enriched
with B. biﬁdum
1.9  108 CFU and S.
thermophilus 0.14  108
Placebo (formula
without probiotic)
During hospital
stay
Diarrhea (5 loose or
watery stools in a 24-h
period)
a In all cases, an answer of 'yes' indicates a low risk of bias, and an answer of 'no' indicates a high risk of bias. AAD: antibiotic-associated diarrhea; CFU, colony-forming units; DB, double-blinding.
p
 e
 d
 i
 a
 t
 r
 i
 a
 p
 o
 l
 s
 k
 a
 8
 9
 (
 2
 0
 1
 4
 )
 8
 –
 1
 6
 
11
Table II – Characteristics of excluded studies
Tabela II – Charakterystyka wykluczonych badań
Study (author) Reason for exclusion
Dani et al. [20] Different population (intensive care
unit patients)
Honeycutt et al. [21] Different population (intensive care
unit patients)
Mihatsch et al. [22] Different population (preterm infants)
Rojas et al. [23] Different population (preterm infants)
p e d i a t r i a p o l s k a 8 9 ( 2 0 1 4 ) 8 – 1 61218], probiotic use within 7 days before admission [13, 15,
16], acute gastroenteritis [13–18], gastroenteritis in the ﬁrst
24 h after admission [15, 17], and chronic gastrointestinal
diseases [13, 15, 16].Study or Subgroup
2.2.1 Lactobacill us rhamno sus GG
Hojsak 2010
Szajewska 2001
Subtotal (95% CI)
Total  events
Heterogeneity: Chi² = 1.26, d f = 1 (P = 0.26); I² = 21%
Test for overall effect: Z  = 4.14 (P  < 0.0001)
2.2.4 Lactobacillus reuteri DSM 17938
Wanke 2012
Subtotal (95% CI)
Total events
Heterogenei ty: Not  applicable
Test for  ove ral l eff ect: Z = 0.28 (P =  0.78)
2.2.5 Bifidobacteriu m bifidu m and Stre ptococc us thermop hilu s
Saaved ra 1999
Subtotal (95% CI)
Total  events
Heterogenei ty: Not  applicable
Test for overall effect: Z  = 2.01 (P  = 0.04)
2.2.6 Lactobacillus delbruecki H2B20
Penna 2009
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for  ove ral l eff ect: Z = 0.90 (P =  0.37)
Events
19
3
22
18
18
2
2
10
10
Total
376
45
421
54
54
29
29
72
72
Events
44
12
56
16
16
8
8
6
6
Total
366
36
402
52
52
26
26
67
67
Weigh t
77.0%
23.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Exper ime ntal Control 
Fig. 2 – Probiotics for the prevention o
Ryc. 2 – Probiotyki w zapobiegInterventions
Only a limited number of probiotic microorganisms were
tested. Three RCTs tested LGG [13–15] at a daily dose ranging
from 1  109 CFU [13] to 1  1010 CFU [14] to 6  109 CFU [15].
Other probiotics were tested in single trials only, and they
included Lactobacillus reuteri DSM 17938 [16] at a dose of
108 CFU, Lactobacillus delbrueckii [17] at a dose of 2.6  108 CFU,
and Biﬁdobacterium biﬁdum (1.9  108 CFU) & Streptococcus ther-
mophilus (0.14  108 CFU) [18]. The probiotics were delivered in
the form of fermented milk [13, 17], capsules [14], sachets
[15], drops [16], or milk formula supplemented with probiotics
[18]. In all of the studies, probiotic administration lasted for
the duration of the hospital stay.M-H, Fixed,  95% CI
0.42 [0.25, 0.71]
0.20 [0.06,  0.66 ]
0.37 [0.23, 0. 59]
1.08 [0.62,  1.89 ]
1.08 [0.62,  1.89]
0.22 [0.05, 0.96]
0.22 [0.05, 0. 96]
1.55 [0.60,  4.03 ]
1.55 [0.60,  4.03]
Risk  Rat io Risk  Rat io
M-H, Fixed,  95% CI
0.01 0.1 1 10 10 0
Favour s exper imental Favours control
f healthcare-associated diarrhea
aniu biegunce szpitalnej
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In ﬁve of the included RCTs [13, 15–18], the primary outcome
measure was the incidence of diarrhea. In one RCT [14], the
primary outcome measure was rotavirus gastroenteritis.
Stool samples for rotavirus testing were collected at admis-
sion [14, 16] when diarrhea occurred during hospitalization
[13–16, 18], once a week [15, 18], at discharge [14] or at 72 h
after discharge if there was no diarrhea during the hospital
stay [14]. In one study [17] no rotavirus testing was
performed.
Effects of interventions
Diarrhea (Fig. 2)
The pooled results of 2 RCTs [13, 15] showed that admini-
stration of LGG compared with placebo reduced the risk of
healthcare-associated diarrhea (n = 823, RR 0.37, 95% CI 0.23–
0.59). One small RCT [18] showed that administration of B.
biﬁdum & Str. thermophilus compared with placebo reduced
the risk of healthcare-associated diarrhea (n = 55, RR 0.22,Study or Subgroup
2.1.1 Lactobacillus rhamnosus GG
Hojsak 2010
Mastretta 2002
Szajewska 2001
Subtotal (95% CI)
Total  events
Heterogenei ty: C hi² = 2.56, df = 2 (P = 0.28);  I² = 22%
Test for  ove ral l eff ect: Z = 2.49 (P = 0.01)
2.1.2 Bifidobacteriu m bifidu m and Stre ptococc us thermop hilu s
Saavedra 1999
Subtotal (95% CI)
Total  events
Heterogenei ty: N ot  applicable
Test for  ove ral l eff ect: Z = 2.19 (P = 0.03)
2.1.4 Lactobacill us re uter i DSM 1793 8
Wanke 2012
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z  = 0.16 (P  = 0.87)
Eve nts
0
15
1
16
3
3
10
10
Total
376
114
45
535
29
29
54
54
Events
2
22
6
30
10
10
9
9
Total
366
106
36
508
26
26
52
52
Weight
7.9%
71.2%
20.8%
100.0%
100.0%
100.0%
100.0%
100.0%
Experi mental Control 
Fig. 3 – Probiotics for the preventi
Ryc. 3 – Probiotyki w zapobiegan95% CI 0.05 to 0.96). Administration of two other probiotics
(i.e., L. reuteri DSM 17938 and L. delbrueckii H2B20) did not
reduce the risk of diarrhea.
Rotavirus gastroenteritis (Fig. 3)
The pooled results of 3 RCTs [13–15] showed that admini-
stration of LGG compared with placebo signiﬁcantly reduced
the risk of rotavirus gastroenteritis (3 RCTs, n = 1043, RR
0.49, 95% CI % CI 0.28–0.86). One small RCT [18] showed that
administration of B. biﬁdum & Str. thermophilus compared
with placebo reduced the risk of rotavirus gastroenteritis
(n = 55, RR 0.27, 95% CI 0.08–0.87).
Asymptomatic rotavirus infection (Fig. 4)
The pooled results of 2 RCTs showed that administration of
LGG compared with placebo did not reduce the risk of
asymptomatic rotavirus infection (2 RCTs, n = 301, RR 1.39,
95% CI 0.74–2.62) [14, 15]. In contrast, administration of B.
biﬁdum & Str. thermophilus compared with placebo reduced
the risk of rotavirus asymptomatic infection (1 RCT, n = 55,
RR 0.27, 95% CI 0.08–0.87) [18].M-H,  Fixe d, 95%  CI
0.19 [0.01,  4.04 ]
0.63 [0.35,  1.16 ]
0.13 [0.02,  1.06 ]
0.49 [0.28, 0. 86]
0.27 [0.08,  0.87 ]
0.27 [0.08,  0.87]
1.07 [0.47, 2.42]
1.07 [0.47,  2.42]
Risk Rat io Risk Rat io
M-H,  Fixe d, 95%  CI
0.005 0.1 1 10 20 0
Favour s exper imental Favours control
on of rotavirus gastroenteritis
iu biegunce rotawirusowej
Study or Subgroup
2.4.1 Lactobacill us rhamno sus LG G
Mastretta 2002
Szajewska 2001
Subtotal (95% CI)
Total  events
Heterogenei ty: Chi² = 0.09, df = 1 (P = 0.77);  I² = 0%
Test for  ove ral l eff ect: Z = 1.02 (P = 0.31)
2.4.3 Bifidobacteriu m bifidu m and Stre ptococc us thermop hilu s
Saavedra 1999
Subtotal (95% CI)
Total  events
Heterogenei ty: Not  applicable
Test for  ove ral l eff ect: Z = 2.19 (P = 0.03)
Events
14
8
22
3
3
Total
114
45
159
29
29
Events
10
4
14
10
10
Total
106
36
142
26
26
Weigh t
70.0%
30.0%
100.0%
100.0%
100.0%
M-H, Fixed,  95% CI
1.30 [0.60,  2.80 ]
1.60 [0.52,  4.89 ]
1.39 [0.74,  2.62]
0.27 [0.08,  0.87 ]
0.27 [0.08,  0.87]
Experi mental Control Risk Rat io Risk Rat io
M-H, Fixed,  95% CI
0.01 0. 1 1 10 10 0
Favour s exper imental Favours control
Fig. 4 – Probiotics for the prevention of asymptomatic rotavirus infection
Ryc. 4 – Probiotyki w zapobieganiu bezobjawowej infekcji rotawirusowej
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Five trials reported data about the duration of hospitaliza-
tion [13–16, 18]. However, we were not able to perform
a meta-analysis because of the different presentations of
the results (mean with standard deviation, mean with no
standard deviation or median). However, none of the studies
reported a signiﬁcant difference between the probiotic
groups and the placebo groups for the duration of hospital
stay and duration of diarrhea.
Harms
The probiotics were well tolerated, and no harm was
reported in the included trials.
Discussion
Summary of evidence
This systematic review and meta-analysis demonstrated
that only a limited number of probiotics for preventing
healthcare-associated diarrhea have been evaluated. Only
some of them may reduce the risk of diarrhea and rotavirus
gastroenteritis in hospitalized children. As reported earlier
by us, the strongest evidence is with regard to LGG. In
hospitalized children, the use of LGG reduced the overall
incidence of healthcare-associated diarrhea, including rota-
virus gastroenteritis. Evidence limited to one RCT suggeststhe efﬁcacy of B. biﬁdum & Str. thermophilus. Other studied
probiotics, i.e., L. reuteri DSM 17938 and L. delbrueckii H2B20,
were ineffective. However, again, the evidence is limited to
single trials only.
Strengths and limitations
This systematic review adds to previously published data,
as it allowed identiﬁcation of all probiotics whose efﬁcacy
for preventing nosocomial infections has been assessed.
Thus, in addition to LGG, the efﬁcacy of which was reported
by us previously [8], we included data on other microorga-
nisms. This is valuable as, worldwide, the availability of
probiotic products differs. Thus, our systematic review may
have practical implications. It allows one to answer the
question of which of the locally available probiotics, if any,
are effective. In contrast to the authors of many other meta-
analyses, we abstained from pooling data on different
probiotics. This is because it has been repeatedly questio-
ned, also by our group, whether it is appropriate to pool
data on different probiotic microorganisms [18]. We strongly
support the view that pooling data from different genera,
species, and strains may result in misleading conclusions.
Efforts were made to identify all published evidence. For
example, we searched several databases with no language
restrictions. However, the possibility of missing data cannot
be excluded. Publication bias remains a possible source of
important bias.
p e d i a t r i a p o l s k a 8 9 ( 2 0 1 4 ) 8 – 1 6 15Agreements and disagreements with other studies or reviews
To our knowledge, except for our review on the efﬁcacy of
LGG [8] there are no other systematic reviews that have
focused exclusively on the effectiveness of probiotics for the
prevention of healthcare-associated diarrhea in hospitalized
children.
Conclusions
In the absence of other effective measures, evidence suppor-
ting the use of LGG to reduce the risk of healthcare-
associated diarrhea is encouraging. With regard to the other
probiotics studied, data, whether positive or negative, are
too limited to draw reliable conclusions. In the future, after
a more universal introduction of rotavirus vaccination, the
burden of nosocomial diarrhea and responsible pathogens
may change as recently documented. In some countries,
such as the US, norovirus has emerged as the leading cause
of medically attended gastroenteritis [19]. If so, the efﬁcacy
of probiotics for preventing nosocomial diarrhea needs to be
reassessed. Further studies are also recommended to add-
ress the cost-effectiveness of using LGG, or other probiotics
with documented efﬁcacy, for the prevention of healthcare-
associated diarrhea. Although none of the included studies
reported adverse events, standardized and clear adverse
event reporting is essential for future trials.
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